The Study
OP04 The Modernized Cardiff Model: Multifaceted Modeling In The Era Of Cardiovascular-Kidney-Metabolic Syndrome
This study is like a video game that pretends to simulate how doctors might treat diabetes, but it didn't actually watch any real patients. It guesses what might happen if doctors used a new rule, but we don't know if that guess is right.
Analysis score
Maximum 0 for a computational/algorithm study.
Where the score came from
Instead of just checking blood sugar to decide diabetes treatment, doctors should also look at heart and kidney risk — this study shows that doing so leads to better outcomes.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 50 / 100
Quality score
Based on clinical experience or non-systematic literature reviews. The lowest level of evidence as they are most susceptible to bias and personal perspective.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — avoiding kidney failure saves money and adds meaningful healthy years of life for patients, which traditional models miss.
- 281% of patients got SGLT2 inhibitors within 5 years when using heart/kidney risk, vs.
- 30% when using only blood sugar.
- 4This saved £10,757 per patient and added 0.73 healthy life years, mostly by preventing kidney damage.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
International Journal of Technology Assessment in Health Care
Year
2024
Authors
Philip McEwan, V. Foos, Jieling Chen, Marc Evans, Geraint Roberts, Robert H Jenkins, Andy Gibson
Related Content
Claims (4)
Doctors should evaluate overall metabolic health when assessing cardiovascular disease risk, rather than focusing only on single blood test results.
Computational models show that current economic models focused only on blood sugar miss significant cost savings from preventing kidney problems when SGLT2 inhibitors are used in patients with cardiovascular risk, leading to an estimated GBP2.8 billion in savings for national health payers.
A new computer model for managing type 2 diabetes that uses cardiovascular risk scores, kidney disease status, and body mass index of 35 or higher provides better alignment with clinical guidelines than models that rely only on blood sugar levels.
Among patients newly diagnosed with type 2 diabetes, using a treatment plan focused on heart health and other conditions leads to 81% starting an SGLT2 inhibitor within five years, while a plan focused only on blood sugar leads to 0% starting one; this difference results in 0.73 more years of healthy life and GBP10,757 in cost savings per person, mainly because fewer kidney problems occur.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.